Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Grillo

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Blood|October 6, 1997
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphomaD G Maloney, A J Grillo-López, C A White, et al.
Nefrologia|July 24, 2017
Prospective evaluation of the development of contrast-induced nephropathy in patients with acute coronary syndrome undergoing rotational coronary angiography vs. conventional coronary angiography: CINERAMA studyDiego Fernández-Rodríguez, José J Grillo-Pérez, Horacio Pérez-Hernández, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
ACS Chemical Biology|December 16, 2024
The Impact of Sugar Conformation on the Single-Stranded DNA Selectivity of APOBEC3A and APOBEC3B EnzymesMackenzie K Wyllie, Clare K Morris, Nicholas H Moeller, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Blood|October 6, 1997
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphomaD G Maloney, A J Grillo-López, C A White, et al.
Nefrologia|July 24, 2017
Prospective evaluation of the development of contrast-induced nephropathy in patients with acute coronary syndrome undergoing rotational coronary angiography vs. conventional coronary angiography: CINERAMA studyDiego Fernández-Rodríguez, José J Grillo-Pérez, Horacio Pérez-Hernández, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
European Journal of Nuclear Medicine|August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaG A Wiseman, C A White, M Stabin, et al.
ACS Chemical Biology|December 16, 2024
The Impact of Sugar Conformation on the Single-Stranded DNA Selectivity of APOBEC3A and APOBEC3B EnzymesMackenzie K Wyllie, Clare K Morris, Nicholas H Moeller, et al.
Pageof 9